VR Adviser, LLC
- SEC CIK
- 0001615982
- Latest filing
- Aug 14, 2026
Holdings in Q4 2022
Holdings as of Dec 31, 2022, filed May 15, 2023. Long positions only; changes compare share counts with Q3 2022.
- Positions
- 28
- −3 vs. Q3 2022
- Portfolio value
- $593.6M
- −$54.5M (−8.4%) vs. Q3 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| RLYBRallybio Corp | COM | 268,532 | $1.76M | 0.3% | 00.0% | Unchanged | History |
| Affimed N VN01045108 | COM | 1,428,571 | $1.77M | 0.3% | 00.0% | Unchanged | – |
| ATYRaTYR PHARMA INC | COM NEW | 1,171,436 | $2.57M | 0.4% | −227,453−16.3% | Reduced | History |
| INZYInozyme Pharma, Inc. | COM | 2,709,987 | $2.85M | 0.5% | 00.0% | Unchanged | History |
| LYRALyra Therapeutics, Inc. | COM | 924,170 | $2.90M | 0.5% | 00.0% | Unchanged | History |
| FULCFulcrum Therapeutics, Inc. | COM | 447,326 | $3.26M | 0.5% | −752,674−62.7% | Reduced | History |
| TRVITrevi Therapeutics, Inc. | COM | 3,050,022 | $5.89M | 1.0% | 00.0% | Unchanged | History |
| MRNSMarinus Pharmaceuticals, Inc. | COM NEW | 1,770,705 | $7.05M | 1.2% | −1,386,098−43.9% | Reduced | History |
| LIANYLianBio | SPONSORED ADS | 4,793,047 | $7.86M | 1.3% | −585,294−10.9% | Reduced | History |
| MISTMilestone Pharmaceuticals Inc. | COM | 2,208,812 | $8.75M | 1.5% | −216,925−8.9% | Reduced | History |
| SVRASavara Inc | COM | 6,351,531 | $9.84M | 1.7% | +1,796,493+39.4% | Added | History |
| PRVBProvention Bio, Inc. | COM | 1,118,653 | $11.8M | 2.0% | 00.0% | Unchanged | History |
| Vectivbio Hldg AGH9060V101 | ORD SHS | 1,866,000 | $16.2M | 2.7% | +1,866,000 | New | – |
| ANNXAnnexon, Inc. | COM | 3,220,050 | $16.6M | 2.8% | 00.0% | Unchanged | History |
| CABACabaletta Bio, Inc. | COM | 1,895,285 | $17.5M | 3.0% | +1,895,285 | New | History |
| MRUSMerus N.V. | COM | 1,226,214 | $19.0M | 3.2% | +1,226,214 | New | History |
| NVAXNovavax Inc | COM NEW | 1,879,894 | $19.3M | 3.3% | +1,879,894 | New | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 2,916,667 | $19.7M | 3.3% | +2,916,667 | New | History |
| PLRXPliant Therapeutics, Inc. | COM | 1,080,000 | $20.9M | 3.5% | 00.0% | Unchanged | History |
| JBIOJade Biosciences, Inc. | COM | 747,869 | $21.9M | 3.7% | −86,058−10.3% | Reduced | History |
| DICEDICE Therapeutics, Inc. | COM | 819,000 | $25.6M | 4.3% | +54,021+7.1% | Added | History |
| CELCCelcuity Inc. | COM | 2,105,386 | $29.5M | 5.0% | +2,105,386 | New | History |
| GHRSGH Research PLC | ORDINARY SHARES | 3,517,125 | $34.2M | 5.8% | +183,971+5.5% | Added | History |
| TERNTerns Pharmaceuticals, Inc. | COM | 3,707,891 | $37.7M | 6.4% | 00.0% | Unchanged | History |
| COGTCogent Biosciences, Inc. | COM | 4,038,117 | $46.7M | 7.9% | 00.0% | Unchanged | History |
| AXSMAxsome Therapeutics, Inc. | COM | 670,718 | $51.7M | 8.7% | +670,718 | New | History |
| ACRSAclaris Therapeutics, Inc. | COM | 4,563,962 | $71.9M | 12.1% | 00.0% | Unchanged | History |
| VRDNViridian Therapeutics, Inc. | COM | 2,699,865 | $78.9M | 13.3% | +569,557+26.7% | Added | History |
Sold out since Q3 2022 (10)
Positions held at the end of Q3 2022 that are gone from this filing.
| Security | Class | Shares in Q3 2022 | Value in Q3 2022 | % of portfolio in Q3 2022 | History |
|---|---|---|---|---|---|
| TCDATricida, Inc. | COM | 9,050,064 | $94.8M | 14.6% | History |
| RLMDRelmada Therapeutics, Inc. | COM | 1,518,056 | $56.2M | 8.7% | History |
| GOSSGossamer Bio, Inc. | COM | 1,747,000 | $20.9M | 3.2% | History |
| TILInstil Bio, Inc. | COM | 4,105,779 | $19.9M | 3.1% | History |
| AKUSAkouos, Inc. | COM | 2,800,566 | $18.9M | 2.9% | History |
| VTYXVentyx Biosciences, Inc. | COM | 207,925 | $7.26M | 1.1% | History |
| RXDXPrometheus Biosciences, Inc. | COM | 121,663 | $7.18M | 1.1% | History |
| ALTAltimmune, Inc. | COM NEW | 369,306 | $4.72M | 0.7% | History |
| IMCRImmunocore Holdings plc | ADS | 94,605 | $4.44M | 0.7% | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 75,000 | $2.11M | 0.3% | History |